Inspire Medical Systems, Inc. is a medical technology company. The Company is focused on the development and commercialization of advanced, minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire therapy is FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. It has developed a novel, closed-loop solution that continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The Company sells its Inspire system to hospitals and ambulatory surgery centers (ASCs) in the United States (U.S.) and in select countries in Europe and Japan through a direct sales organization and sells its Inspire system in Singapore and Hong Kong through distributors. Its direct sales force engages in sales efforts and promotional activities focused on ear, nose and throat (ENT) physicians and sleep centers.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 45.96% year-on-year.
Fairly Valued
The company’s latest PE is 11.26, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 34.93M shares, decreasing 15.55% quarter-over-quarter.
Held by John Hussman
Star Investor John Hussman holds 12.83K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.03.